GlassScriptPhysician profile
Eric A Garcia
NPI 1194774596
$2,558.22
in general payments reported to CMS, 2019-2025
22 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $36.36 · 2021: $64.03 · 2022: $451 · 2023: $758 · 2024: $854 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,725.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $605.79 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $334.51 | 2019-2024 | Farxiga, Breztri |
| Abbvie INC. | $305.26 | 2022-2024 | |
| Gilead Sciences, INC. | $275.10 | 2023-2025 | Biktarvy |
| Pfizer INC. | $225.44 | 2022-2024 | |
| Astellas Pharma US INC | $169.73 | 2022-2024 | Veozah, Myrbetriq |
| Dexcom, INC. | $120.73 | 2021-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $87.38 | 2022-2023 | Emgality, Jardiance |
| Amgen INC. | $84.01 | 2023-2024 | Repatha, Otezla, Prolia |
| Abbott Laboratories | $67.11 | 2023-2024 | Freestyle Libre 2 |
| Scilex Pharmaceuticals INC. | $48.25 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.03 | 2022 | |
| Glaxosmithkline, LLC. | $30.98 | 2020-2023 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $26.55 | 2024 | Rexulti |
| Corium, LLC | $25.51 | 2023 | Azstarys |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $23.17 | 2024 | Senza |
| Philips North America LLC | $19.44 | 2024 | (Ck7) Extended Holter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.85 | 2023 | Jardiance, Tradjenta |
| Kowa Pharmaceuticals America, INC. | $15.84 | 2023 | Livalo |
| Merck Sharp & Dohme LLC | $15.13 | 2019 | |
| Lucid Diagnostics INC. | $13.41 | 2024 | |
| Novartis Pharmaceuticals Corporation | $13.00 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.